Computerized Thermal Imaging, Inc. Receives Approval to be Listed on Nasdaq

Business Wire, June 27, 2000

Business Editors

LAYTON, Utah--(BUSINESS WIRE)--June 27, 2000

Computerized Thermal Imaging, Inc. (OTCBB symbol: COII) announced today that its stock has been approved for listing on the Nasdaq National Market. The Company's common stock will continue to trade under the symbol COII. The Company anticipates that trading of its common stock on Nasdaq will begin on June 29, 2000.

"Our move to Nasdaq is a milestone that recognizes our continued growth and maturity and provides our more than 28,000 shareholders with a broader and more stable market environment. We are particularly pleased to make this announcement in connection with our stockholders meeting," stated David Packer, CTI president. "We believe that this move opens our doors to institutional investors that have heretofore remained on the sidelines and provides access to the capital markets to move us beyond the development stage."

CTI is seeking FDA approval for the use of the Computerized Thermal Imaging System as an adjunctive diagnostic test to the mammogram and clinical examination for the detection of breast cancer. The test is simple, painless and involves no radiation, breast compression, electrodes, electrical current or skin contact. CTI also recently announced the evaluation of their technology for new occupational medicine applications.

Computerized Thermal Imaging, Inc. is in business to improve the quality of life through superior diagnostics. Information about CTI can be found on the Internet at www.cti-net.com or by calling CTI Public Affairs at (801) 926-1113.

Except for historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In addition to the factors set forth above, other important factors that could cause actual results to differ materially include, but are not limited to technical risks associated with new technology development, government regulatory approvals or continued working capital. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained from time to time in the Company's SEC filings. Copies of these filings may be obtained by contacting the Company or the SEC.